Peregrine Pharmaceuticals (NASDAQ:PPHM) took a major hit in September after admitting a trial data mix-up for its top drug candidate bavituximab. Since that day, shares had fallen around 80%. Today however, shares were back on the rise, up a healthy 26% (from a much lower base). In this video, Motley Fool health care analyst Brenton Flynn discusses what could be driving share prices today.
